The RMGP Biopharma Fund targets
innovative early stage Biopharma
In partnership with FutuRx, an Israel-based, globally focused drug development platform,
founded by Orbimed, Johnson&Johnson and Takeda.
Early-stage exits in 2016,
60% of all biopharma exits.
An industry shift towards early-stage deals.
Driven by rising cost of drug development, big pharma is seeking innovative de-risked assets. As a result, recent years saw a steep increase in early-stage M&A and licensing deals.
BioPharma remains a strong investment opportunity.
Aging population, increase in healthcare spending,
and advancements in biology,
make biopharma an attractive sector.
Life science companies
Israel is an innovation Hub.
Israel is a leader in R&D spending and IP generation per capita, with a rapidly growing pipeline in a variety of healthcare segments.